| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aerovate Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 12,500 | $204,625 | $16.37 | 05 Jun 2024 | Direct |
| Surrozen, Inc./DE | Former Director | Common Stock | 30,000 | $11,400 | $0.3800 | 11 Aug 2021 | Direct |
| Oyster Point Pharma, Inc. | Director | Common Stock | 0 | $11.20 | 03 Jan 2023 | Direct | |
| Oyster Point Pharma, Inc. | Director | Stock Option (Right to Buy) | 0 | 03 Jan 2023 | Direct | ||
| Surrozen, Inc./DE | Former Director | Class B Ordinary Shares | 0 | 11 Aug 2021 | Direct |